Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation

British Journal of Haematology

Volumn 135, Issue 4, 2006, Pages 486-491

  Chang, Hong ^a,c   Qi, Xiaoying ^a   Trieu, Young ^a   Xu, Wei ^a   Reader, Jocelyn C ^b   Ning, Yi ^b   Reece, Donna ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

1q21; Cyclin kinase subunit 1B; Fluorescence in situ hybridisation; Multiple myeloma

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE; CYCLIN DEPENDENT KINASE 1; CYCLIN KINASE SUBUNIT 1B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE ATROPHY; CANCER CHEMOTHERAPY; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CKS1B GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENETIC STABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ONCOGENE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; SIGNAL DETECTION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 1; CYCLIN-DEPENDENT KINASES; EPIDEMIOLOGIC METHODS; FEMALE; GENE AMPLIFICATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 33750075151     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06325.x     Document Type: Article

References (34)

1. Avet-Loiseau, H., Andree-Ashley, L.E., Moore, D.II., Mellerin, M.P., Feusner, J., Bataille, R. & Pallaricini, M.G. (1997) Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes, Chromosomes & Cancer, 19, 124-133.
2. Bergsagel, P.L. & Kuehl, W.M. (2001) Chromosome translocations in multiple myeloma. Oncogene, 20, 5611-5622.
3. Bergsagel, P.L., Chesi, M., Nardini, E., Brents, L.A., Kirby, S.L. & Kuehl, W.M. (1996) Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 93, 13931-13936.
4. Bergsagel, P.L., Kuehl, W.M., Zhan, F., Sawyer, J., Barlogie, B. & Shaughnessy, J. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in MM. Blood, 106, 296-303.
5. Chang, H., Bouman, D., Boerkoel, C.F., Stewart, A.K. & Squire, J.A. (1999) Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia, 13, 105-109.
6. Chang, H., Sloan, S., Li, D. & Stewart, A.K. (2004a) Multiple myeloma involving central nervous system: high frequency of p53 deletions. British Journal of Haematology, 127, 280-284.
7. Chang, H., Sloan, S., Li, D., Zhuang, L., Yi, Q.L., Chen, C.I., Reece, D., Chun, K. & Stewart, K.A. (2004b) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 125, 64-68.
8. Chang, H., Qi, C., Yi, Q.L., Reece, D. & Stewart, A.K. (2005a) p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood, 105, 358-360.
9. Chang, H., Samiee, S., Qi, W.Y., Yi, Q.L., Mikhael, J., Chen, C., Trudel, S., Mikhael, J., Reece, D. & Stewart, A.K. (2005b) Genetic risk identifies myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplantation, 36, 793-796.
10. Chang, H., Sloan, S., Li, D. & Patterson, B. (2005c) Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 156, 150-153.
11. Cigudosa, J.C., Rao, P.H., Calasanz, M.J., Odero, M.D., Michalli, J., Jhanwar, S.C. & Chaganti, R.S. (1998) Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood, 91, 3007-3010.
12. Cremer, F.W., Bila, J., Buck, I., Kartal, M., Hose, D., Ittrich, C., Benner, A., Raab, M.S., Theil, A.C., Moos, M., Goldschmidt, H., Bartram, C.R. & Jauch, A. (2005) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes, Chromosomes & Cancer, 44, 194-203.
13. Drach, J., Ackermann, J., Fritz, E., Kromer, E., Schuster, R., Gisshinger, H., DeSantis, M., Zojer, N., Fiegl, M., Roka, S., Schuster, J., Heinz, R., Ludwig, H. & Huber, H. (1998) Presence of a p53 deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood, 92, 802-809.
14. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Lai, J.L., Leleu, X., Jouet, J.P., Bauters, F., Harousseau, J.L., Bataille, R., Mary, J.Y., Intergroupe Francophone du Myelome. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum beta-2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97, 1566-1571.
15. Fonseca, R., Bailey, R.J., Ahmann, G.J., Rajkumar, S.V., Hoyer, J.D., Lust, J.A., Kyle, R.A., Gertz, M.A., Greipp, P.R. & Dewald, G.W. (2002a) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood, 100, 1417-1424.
16. Fonseca, R., Harrington, D., Oken, M.M., Dewald, G.W., Bailey, R.J., Van Wier, S.A., Henderson, K.J., Blood, E.A., Rajkumar, S.V., Kay, N.E., Van Ness, B. & Greipp, P.R. (2002b) Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosomalities (delta13) in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Research, 62, 715-720.
17. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M.M., Kyle, R.A., Dewald, G.W., Van Ness, B., Van Weir, S.A., Henderson, K.J., Bailey, R.J. & Greipp, P.R. (2003) Clinical biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
18. Fonseca, R., Van Wier, S., Chng, W.J., Ketterling, R., Lacy, M., Dispenzieri, A. & Bergsagel, P.L. (2005) Low level amplification (duplication) of 1q21 in myeloma and prognosis: the role of CKS1B. Blood, 106, 185a.
19. Skp2-mediated ubiquitinylation of p27. Nature Cell Biology, 3, 321-324.
20. Gutierrez, N.C., Garcia, J.L., Hernandez, J.M., Lumbreras, E., Castellanos, M., Rasillo, A., Mateo, G., Hernandez, J.M., Perez, S., Orfao, A. & San Miguel, J.F. (2004) Prognostic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood, 104, 2661-2666.
21. Hadwiger, J.A., Wittenberg, C., Mendenhall, M.D. & Reed, S.I. (1989) The Saccharomyces cerevisiae CKS1 gene, a homolog of the Schizosaccharomyces prombe suc1+ gene, encodes a subunit of the Cdc28 protein kinase complex. Molecular and Cellular Biology, 9, 2034-2041.
22. Kaufmann, H., Ackermann, J., Baldia, C., Nosslinger, T., Wieser, R., Seidl, S., Sagaster, V., Gisslinger, H., Jager, U., Pfeilstocker, M., Zielinski, C. & Drach, J. (2004) Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia, 18, 1879-1882.
23. Keats, J.J., Reiman, T., Maxwell, C.A., Taylor, B.J., Larratt, L.M., Mant, M.J., Belch, A.R. & Pilarski, L.M. (2003) In multiple myeloma, t(4;14)(p16;32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood, 101, 1520-1529.
24. Kitajima, S., Kudo, Y., Ogawa, I., Bashir, T., Kitagama, M., Miyauchi, M., Pagano, M. & Takata, T. (2004) Role of Cks1 overexpression in oral squamous cell carcinomas. American Journal of Pathology, 165, 2147-2155.
25. Kuehl, W.M. & Bergsagel, P.L. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175-187.
26. Masuda, T., Inoue, H., Nishida, K., Sonoda, H., Yoshikawa, Y., Kakeji, Y., Utsunomiya, T. & Mori, M. (2003) Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clinical Cancer Research, 9, 5693-5698.
27. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.L., Bataille, R., Avet-Loiseau, H., Intergroupe Francophone du Myelome. (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood, 100, 1579-1583.
28. Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. (1995) Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genetics and Cytogenetics, 82, 41-49.
29. Sawyer, J.R., Tricot, G., Mattox, S., Jagannath, S. & Barlogie, B. (1998) Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood, 91, 1732-1741.
30. Sawyer, J.R., Tricos, G., Lukacs, J.L., Binz, R.L., Tian, E., Barlogie, B. & Shaughnessy, Jr, J. (2005) Genetic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes, Chromosomes & Cancer, 42, 95-106.
31. Shapira, M., Ben-Izhak, O., Linn, S., Futerman, B., Minkov, I. & Hershko, D.D. (2005) The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer, 103, 1336-1346.
32. Shaughnessy, J. (2005) Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 and an aggressive clinical course in multiple myeloma. Hematology, 10, 117-126.
33. Spruck, C., Strohmaier, H., Waston, M., Smith, A.P., Ryan, A., Krek, T.W. & Reed, S.I. (2001) A CDK-dependent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Molecular Cell, 7, 639-650.
34. Wuilleme, S., Robillard, N., Lode, L., Magrangeas, F., Beris, H., Harousseau, J.L., Proffitt, J., Minvielle, S., Avet-Loiseau, H., Intergroupe Francophone de Myelome. (2005) Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia, 19, 275-278.